中国临床药学杂志

目的 考察替考拉宁临床使用合理性。方法 选取2020年10月至2022年12月使用替考拉宁的病历资料，依据药品说明书、指南、相关文献资料及专家意见细分出4个一级评价指标、11个二级评价指标，采用逐步加权评估分析比率法（SWARA）确定各评价指标权重，运用赋权后的逼近理想解排序（TOPSIS）法对病历进行点评，综合评价替考拉宁临床使用合理性。结果 根据SWARA法计算的权重中占比较高的是适应证、用法用量及给药方式（权重分别为0.273、0.188及0.139）。结合赋权TOPSIS法点评的100份病历中，使用合理的有35份（占35.00%），使用基本合理的有29份（占29.00%）及不合理的有36份（占36.00%）。结论 采用SWARA-TOPSIS相结合的方法对替考拉宁临床使用进行综合评价，反映出临床使用过程中仍存在一定问题，应进一步加强管理，促进其合理正确使用。

AIM To evaluate the rational use of teicoplanin in clinical practice. METHODS Patients who used teicoplanin from October 2020 to December 2022 were selected as the research subjects. Based on drug instructions,guidelines, relevant literature and expert opinions, 4 first-level indicators and 11 second-level evaluation indicators were subdivided. The step-wise weighted assessment ratio analysis(SWARA) method was employed to determine the weight of each evaluation indicator. The weighted techinque for order preference by similarity to ideal solution(TOPSIS) method was utilized to comment on cases and comprehensively evaluate the rationality of clinical use of teicoplanin. RESULTS Among the weights calculated by the SWARA method, indications, drug selection, usage and dosage, and administration route had relatively high proportions(0.273, 0.188, and 0.139). Among the 100 cases commented on by the weighted TOPSIS method,35 cases(35.00%) were reasonable in use, 29 cases(29.00%) were basically reasonable in use, and 36 cases(36.00%) were unreasonable in use. CONCLUSION A combined method of SWARA and TOPSIS is employed to conduct a comprehensive evaluation of the clinical use of teicoplanin. It reflects that there are still certain problems in the clinical use process.Therefore, further management should be strengthened to promote its rational and correct use.